Experimental HCV Drugs
Experimental HCV Drugs
EASL 2013: Hep C Quad Regimens Quashed, but Some Components Go Forward
- Details
- Category: HCV Treatment
- Published on Tuesday, 30 April 2013 00:00
- Written by Liz Highleyman
A pair of 4-drug interferon-based hepatitis C regimens worked well, but further study has been halted after a few patients experienced serious adverse events, according to a set of presentations last week at the EASL International Liver Congress (EASL 2013) this week in Amsterdam. While this type of quad regimen has little if any future, some of the component drugs remain promising.
EASL 2013: Second-generation Protease Inhibitor Faldaprevir Cures up to 80% of Genotype 1 Hepatitis C
- Details
- Category: HCV Treatment
- Published on Monday, 29 April 2013 00:00
- Written by Keith Alcorn
A second-generation HCV protease inhibitor, faldaprevir (formerly BI 201335), cured up to 80% of previously untreated people with genotype 1 hepatitis C virus infection when combined with pegylated interferon and ribavirin, Peter Ferenci of the Medical University of Vienna reported on Saturday at the EASL International Liver Congress (EASL 2013) in Amsterdam. A response gap was observed, however, between HCV subtypes 1a and 1b.
Coverage of the 2013 EASL International Liver Congress
- Details
- Category: HBV Treatment
- Published on Saturday, 27 April 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) in Amsterdam, April 24-28, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, and prevention and treatment of hepatocellular carcinoma.
4/27/13
EASL 2013: Daclatasvir + Sofosbuvir Offers Rescue Therapy after Current Standard of Care
- Details
- Category: HCV Treatment
- Published on Sunday, 28 April 2013 00:00
- Written by Liz Highleyman
An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C patients who did not respond to interferon-based triple therapy using the approved HCV protease inhibitors boceprevir (Victrelis) or telaprevir (Incivek), according to a report presented at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
EASL 2013: MK-5172 Boosts Interferon/Ribavirin Response Regardless of IL28B Status
- Details
- Category: HCV Treatment
- Published on Saturday, 27 April 2013 00:00
- Written by Liz Highleyman
The experimental HCV protease inhibitor MK-5172 increased sustained response rates to over 90% when added to pegylated interferon/ribavirin in a study of previously untreated genotype 1 hepatitis C patients, researchers reported this week at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
More Articles...
- EASL 2013: Sofosbuvir + Ribavirin Cures Most Genotype 2 Hepatitis C, but Genotype 3 Response Is Lower
- EASL 2013: AbbVie Interferon-free Combination Cures Over 90% of Hepatitis C Genotype 1
- EASL 2013: International Liver Congress Kicks Off with Hep C New Drug Highlights
- Janssen Submits Approval Requests for New Hepatitis C Drug Simeprevir
Web Design and Development by